Loading clinical trials...
Loading clinical trials...
A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Conditions
Interventions
Alisertib
Laboratory Biomarker Analysis
Locations
50
United States
Hartford Hospital
Hartford, Connecticut, United States
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, United States
The Hospital of Central Connecticut
New Britain, Connecticut, United States
Florida Hospital Orlando
Orlando, Florida, United States
University of Hawaii Cancer Center
Honolulu, Hawaii, United States
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, United States
Start Date
August 1, 2012
Primary Completion Date
August 1, 2014
Completion Date
February 11, 2017
Last Updated
July 23, 2019
NCT04200443
NCT03880019
NCT02601209
NCT00025506
NCT01098630
NCT00031629
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions